A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Wagner, Andrew J.
Banerji, Udai
Mahipal, Amit
Somaiah, Neeta
Hirsch, Heather Anne
Fancourt, Craig
Levonas, Amy
Lam, Raymond
Meister, Amy
Kemp, Ramon Karmel
Knox, Clayton
Rose, Shelonitda
Hong, David S.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Inst Canc Res, London SW3 6JB, England
[3] Royal Marsden NHS Fdn Trust, London, England
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10564
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
    Wagner, Andrew J.
    Banerji, Udai
    Mahipal, Amit
    Somaiah, Neeta
    Hirsch, Heather
    Fancourt, Craig
    Johnson-Levonas, Amy O.
    Lam, Raymond
    Meister, Amy K.
    Russo, Giuseppe
    Knox, Clayton D.
    Rose, Shelonitda
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (12) : 1304 - +
  • [2] A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)
    Ravandi, Farhad
    Gojo, Ivana
    Patnaik, Mrinal M.
    Minden, Mark D.
    Kantarjian, Hagop
    Johnson-Levonas, Amy O.
    Fancourt, Craig
    Lam, Raymond
    Jones, Mary Beth
    Knox, Clayton D.
    Rose, Shelonitda
    Patel, Payal Shah
    Tibes, Raoul
    LEUKEMIA RESEARCH, 2016, 48 : 92 - 100
  • [3] A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
    Ravandi, Farhad
    Gojo, Ivana
    Patnaik, Mrinal Mahesh
    Minden, Mark D.
    Kantarjian, Hagop M.
    Levonas, Amy
    Fancourt, Craig
    Lam, Raymond
    Meister, Amy
    Jones, Mary Elizabeth
    Kemp, Ramon Karmel
    Knox, Clayton
    Rose, Shelonitda
    Patel, Payal Shah
    Tibes, Raoul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
    de Jonge, Maja
    de Weger, Vincent A.
    Dickson, Mark A.
    Langenberg, Marlies
    Le Cesne, Axel
    Wagner, Andrew J.
    Hsu, Karl
    Zheng, Wei
    Mace, Sandrine
    Tuffal, Gilles
    Thomas, Koruth
    Schellens, Jan H. M.
    EUROPEAN JOURNAL OF CANCER, 2017, 76 : 144 - 151
  • [5] A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors
    De Weger, V.
    Varga, A.
    De Jonge, M.
    Langenberg, M.
    Mergui-Roelvink, M.
    Massard, C.
    Van der Vlist, A.
    Devriese, L.
    Goodstal, S.
    Zheng, W.
    Tuffal, G.
    Semiond, D.
    Mace, S.
    Watters, J.
    Demers, B.
    Schellens, J.
    Deutsch, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S55 - S55
  • [6] A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Bell, Maria
    Burkard, Mark E.
    Eickhoff, Jens C.
    Wilding, George
    LoConte, Noelle K.
    Traynor, Anne M.
    Hoang, Tien
    Heideman, Jennifer
    Kolesar, Jill
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
    Plummer, R
    Middleton, M
    Wilson, R
    Jones, C
    Evans, J
    Robson, L
    Steinfeldt, H
    Kaufman, R
    Reich, S
    Calvert, AH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 208S - 208S
  • [8] Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Munster, Pamela N.
    Hollehecque, Antoine
    Argiles, Guillem
    Dajanl, Olav
    Cheng, Jonathan D.
    Wang, Ruixue
    Swift, Ann M.
    Tosolini, Alessandra
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors.
    Gold, PJ
    Refice, S
    West, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 164S - 164S
  • [10] Preclinical Pharmacokinetics of MI-219, a Novel Human Double Minute 2 (HDM2) Inhibitor and Prediction of Human Pharmacokinetics
    Zou, Peng
    Zheng, Nan
    Yu, Yanke
    Yu, Shanghai
    Sun, Wei
    McEachern, Donna
    Yang, Yongsheng
    Yu, Lawrence X.
    Wang, Shaomeng
    Sun, Duxin
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2012, 15 (02): : 265 - 280
12345